Trial reportPsychopharmacology2008
Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.
Trial report in Psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.Psychopharmacology · 2021Pooled it
- Trial
- Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.Psychopharmacology · 2018Trial
- Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency.European archives of psychiatry and clinical neuroscience · 2012Trial
- Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Acute Effects and Long-Term Neuropsychological Consequences of Classic Psychedelics Use.Current topics in behavioral neurosciences · 2026Review
- The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.Biological psychiatry global open science · 2025Article
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.Cellular and molecular life sciences : CMLS · 2024Review
- The Altered States Database: Psychometric data from a systematic literature review.Scientific data · 2022Article
- Models of psychedelic drug action: modulation of cortical-subcortical circuits.Brain : a journal of neurology · 2022Article
- Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.Frontiers in neuroscience · 2022Review
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.Frontiers in psychiatry · 2021Review
- Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.NeuroImage · 2020Article
- N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function.Frontiers in neuroscience · 2018Review
- Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.Current pharmaceutical biotechnology · 2018Review
- Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.Therapeutic advances in psychopharmacology · 2017Review
- Chronic Ketamine Exposure Causes White Matter Microstructural Abnormalities in Adolescent Cynomolgus Monkeys.Frontiers in neuroscience · 2017Article
- Neuropharmacology of N,N-dimethyltryptamine.Brain research bulletin · 2016Review
- Clinical applications of hallucinogens: A review.Experimental and clinical psychopharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAttentional deficits are common symptoms in schizophrenia. Recent evidence suggests that schizophrenic patients show abnormalities in spatial orienting of attention, particularly a deficit of inhibition of return (IOR). IOR is mostly thought to reflect an automatic, inhibitory mechanism protecting the organism from redirecting attention to previously scanned, insignificant locations. Pharmacologic challenges with hallucinogens have been used as models for psychosis.
objectivesThe aim of this study was to investigate the neural correlates underlying orienting of attention in the human N-methyl-D-aspartic acid antagonist and 5-HT2A agonist models of psychosis. MATERIALS AND
methodsFourteen healthy volunteers participated in a randomized, double-blind, cross-over event-related functional magnetic resonance imaging (fMRI) study with dimethyltryptamine (DMT) and S-ketamine. We administered a covert orienting of attention task with nonpredictive peripheral cues, and we scanned the subjects on two separate days at least 14 days apart with a placebo and a verum condition on each day.
resultsDMT, but not S-ketamine, slowed down reaction times significantly. IOR was blunted after DMT, but not after S-ketamine. Relative to placebo, S-ketamine increased activation in the IOR condition in the right superior frontal gyrus, left superior temporal gyrus, and right midfrontal frontal gyrus.
conclusionsThe discrepancy between the behavioral and functional imaging outcome indicates that pharmacological fMRI might be a sensitive tool to detect drug-modulated blood oxygenation level-dependent signal changes in the absence of behavioral abnormalities. Our findings might help to further clarify the contradictory findings of IOR in schizophrenic patients and might, thus, shed more light on possible differential pathomechanisms of schizophrenic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.